Other Mutations: BRAF

NCT05340621: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

NCT05340621
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, BRAF, NF1/2, GNA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Phase 1b; Patients must have tumor with an activating mutation in the RAS pathway
Exclusions: Patients with prior exposure to histone deacetylases (HDAC) inhibitors, pan-deacetylating agents, or valproic acid for the treatment of cancer; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05340621

NCT05144698: RAPA-201 Therapy of Solid Tumors

NCT05144698
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF, ALK, BRCA+, EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have exposure to an anti-PD-(L)1 therapeutic monoclonal antibody therapeutic in the most recent line of prior therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with cancer metastasis to the central nervous system, unless adequately treated
https://ClinicalTrials.gov/show/NCT05144698

Up ↑